IEC 62368-3 Adds EMC Rule for Wearable Biosignal Modules

On January 1, 2027, IEC 62368-3:2026 became a mandatory CE and UKCA compliance item for wearable health monitoring devices that include biosignal acquisition modules such as ECG and EMG. The update matters to wearable device exporters, design teams, compliance managers, test laboratories, and supply chain partners because it turns RF electromagnetic immunity performance into a direct market-access issue for affected products, especially for companies shipping from China to Europe and the UK.

What the new standard requirement confirms

The confirmed facts are limited but clear. The IEC formally released IEC 62368-3:2026 on July 7, 2026 under the title Audio/video, information and communication technology equipment safety - Part 3: Particular requirements for wearable health monitoring devices. Under this new standard, biosignal acquisition modules used for functions such as ECG and EMG are, for the first time, required to pass RF electromagnetic field immunity testing at a level of at least 10 V/m under IEC 61000-4-3 Ed.4. From January 1, 2027, this requirement became a mandatory compliance item for CE and UKCA. The input information also makes clear that Chinese wearable device exports need corresponding upgrades in EMC design and pre-compliance testing processes.

Where the pressure is likely to appear first

Export-oriented wearable device makers

From an industry perspective, manufacturers shipping wearable health monitoring devices into CE and UKCA markets are the first group likely to feel the impact. The reason is straightforward: the new requirement is tied to compliance access rather than optional product differentiation. The business impact is likely to concentrate in product definition, EMC design review, verification planning, and shipment readiness for models that include ECG or EMG signal acquisition functions.

Engineering and compliance teams inside product companies

Analysis shows that internal hardware, EMC, and certification teams will need closer coordination. The issue is not only the existence of a new clause, but the fact that immunity performance now has to be addressed as part of a formal conformity path. What deserves closer attention is whether current design validation and pre-test workflows are already capable of identifying RF immunity risks before formal certification schedules are locked.

Testing and certification service providers

Observably, laboratories and compliance service providers may see greater attention on pre-compliance support, test planning, and interpretation of applicability for wearable health monitoring devices. Their role is likely to become more operationally important in the stages between prototype verification and formal market-entry documentation, because timing and test readiness can affect delivery planning.

Supply chain and export delivery functions

For supply chain coordinators and export program managers, the likely effect is less about the standard text itself and more about execution. Components, module integration, product revision control, and certification document readiness may all require tighter synchronization. Companies serving overseas buyers will also need to watch how the new mandatory item affects client acceptance criteria and delivery communication.

What companies should be checking now

Confirm which products actually fall within scope

The first practical step is product mapping. Companies should identify which wearable devices include biosignal acquisition modules such as ECG or EMG, and which of those products are intended for CE or UKCA markets. This distinction matters because the compliance effect described in the input is tied to those markets and to the specific module type.

Review EMC design and pre-test workflows

What deserves closer attention is whether current EMC development processes were built around earlier assumptions that did not treat this immunity level as a mandatory item for these modules. For companies exporting from China, the input explicitly signals the need to upgrade both EMC design and pre-compliance testing processes, which makes workflow review an immediate operational issue rather than a later documentation exercise.

Separate rule text from delivery impact

Analysis shows that a published standard and a smooth commercial rollout are not the same thing. Companies should distinguish between the formal requirement already in force and the practical implications for lead times, retesting, product revisions, and customer communication. That difference matters when planning launch schedules or managing existing product pipelines.

Prepare customer-facing compliance communication

For teams working with distributors, importers, or OEM clients, it is worth preparing clear explanations of how the new mandatory item affects product status, testing timelines, and technical files. The core concern is not marketing language but consistency in commitments, paperwork, and expectation management during order fulfillment.

Why this looks like more than a short-term compliance update

Observably, this development can be read in two layers. As a near-term change, it is a concrete compliance requirement that directly affects products with ECG and EMG acquisition modules entering CE and UKCA channels from January 1, 2027. As a longer signal, it suggests that wearable health monitoring devices are being assessed with closer attention to the robustness of biosignal functions under electromagnetic exposure. It is more appropriate to understand this as an already effective rule with broader regulatory meaning still worth tracking, rather than as a one-day news item with no follow-on effects.

How the industry should read this development

The main industry significance is not simply that IEC issued another standard revision. The more material point is that EMC immunity for wearable biosignal acquisition modules has moved into a mandatory compliance position for CE and UKCA, which changes the practical threshold for export readiness. A measured reading is appropriate: this is already a real compliance change for affected products, while its broader commercial and process effects will depend on how manufacturers, labs, and customers adapt over the next stages of implementation.

Basis of this article and what still needs verification

This article is based on the user-provided news title, event date, and event summary. For this type of industry update, relevant source categories typically include official standard publications, standard organization documents, regulatory compliance notices, industry association materials, company compliance disclosures, and authoritative trade media reporting. A specific official source link was not provided in the input, so the exact source document path still requires ongoing verification. Continued attention should focus on any later official clarifications, scope interpretations, or implementation notes related to IEC 62368-3:2026 and its CE/UKCA application.